NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treat…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.07 | $-0.27 |
| Estimado | $-0.10 | $-0.07 | $-0.06 | $-0.07 |
| Sorpresa | — | — | -16.7% | -285.7% |
| Métrica | NGEN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -1268.9% | -39.2% | -1229.7% |
| ROA | -190.1% | -30.9% | -159.1% |
| Current Ratio | 1.16 | 2.73 | -1.57 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -190.1% | — |
| ✗Flujo de caja operativo positivo | −CA$19M | −CA$17M |
| ✗Rentabilidad sobre activos al alza | -190.1% | -124.4% |
| ✓Caja operativa/activos supera al ROA | -84.0% | ROA -190.1% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 1.16 | 1.12 |
| ✗Sin aumentar el nº de acciones | 72M | 67M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
NERVGEN PHARMA CORP. cotiza a 1.59 USD y tiene una capitalización bursátil de $171M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud